Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.1052W HIGH $5.15
Volume
1.14 M
Value Traded
1.13 M
Short % Float
4.42%
-3.02%Week
-16.95%1 Month
-24.35%3 Month
-22.93%6 Month
-96.03%5 Year
-96.18%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
262.95 M
EPS (TTM)
-0.14
P/E Ratio
-
Ent. Value
160.32 M
Total Shares
90.99 M
Float Shares
81.53 M
Insiders
10.40%
Institutions
72.87%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
SABS Catalyst Timeline
Dated clinical, regulatory and corporate events for SAB Biotherapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for SAB Biotherapeutics, Inc.
300Total events
10Upcoming
69Tier-1 (high impact)
2021 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Enrollment MilestoneSAB-142Trial
Over 60 clinical sites activated in SAFEGUARD study
Stage 3 new onset type 1 diabetessource ↗
▲Partnership / LicenseSAB-142Corporate
Breakthrough T1D awarded grant to PRISE-hATG study of SAB-142
Stage 3 new onset type 1 diabetessource ↗
◆Poster PresentationSAB-142Presentation
Poster presentation at FOCIS 2026 Annual Meeting on positive clinical translation of a juvenile NHP study for SAB-142
type 1 diabetessource ↗
◆Oral PresentationSAB-142Presentation
Oral presentation at ADA 2026 Scientific Sessions on SAB-142 clinical safety, PK, immunogenicity, and PD following repeat dosing
type 1 diabetessource ↗
▲Oral PresentationSAB-142Presentation
Presentation of additional clinical and mechanistic data from SAB-142 Phase 1 trial at IDS 2026
type 1 diabetessource ↗
▼Equity OfferingCorporate
Closing of $85 million public offering of common stock and pre-funded warrants
▼Equity OfferingCorporate
Pricing of $85 million public offering of common stock and pre-funded warrants
◆Oral PresentationPresentation
Barclays 28th Annual Global Healthcare Conference Fireside Chat
▲Full ResultsSAB-142Clinical Data
Additional Phase 1 data for SAB-142 in established T1D cohort showing C-peptide preservation
type 1 diabetessource ↗
▲Enrollment UpdateSAB-142Trial
SAFEGUARD trial enrolling and dosing participants
type 1 diabetessource ↗
◆Oral PresentationPresentation
Oppenheimer 36th Annual Healthcare Life Sciences Conference Fireside Chat
◆Oral PresentationPresentation
Guggenheim Securities Emerging Outlook: Biotech Summit Fireside Chat
◆Additional DataSAB-142Clinical Data
Additional Phase 1 data including redosing data expected later in 2025
type 1 diabetessource ↗
▲Full ResultsSAB-142Clinical Data
Positive confirmatory Phase 1 results for SAB-142
stage 3 type 1 diabetessource ↗
◆Oral PresentationSAB-142Presentation
Oral e-poster on immunomodulation without sustained lymphodepletion
type 1 diabetessource ↗
▲First Patient DosedSAB-142Trial
First patient dosed in Phase 2b SAFEGUARD trial
newly diagnosed Stage 3 autoimmune type 1 diabetessource ↗
◆Oral PresentationPresentation
Guggenheim Second Annual Healthcare Innovation Conference Fireside Chat
◆Oral PresentationSAB-142Presentation
Oral presentation: Immunomodulation Without Sustained Lymphodepletion
type 1 diabetessource ↗
◆Poster PresentationSAB-142Presentation
Poster presentation: Safety Profile of SAB-142
type 1 diabetessource ↗
◆Poster PresentationSAB-142Presentation
Poster presentation: Novel PK Assay for Measuring SAB-142
type 1 diabetessource ↗
◆Oral PresentationSAB-142Presentation
Oral presentation: Specimen quality for multicenter clinical trials
type 1 diabetessource ↗
▲Trial InitiationSAB-142Trial
Initiated registrational Phase 2b SAFEGUARD study of SAB-142
type 1 diabetessource ↗
▲Trial InitiationSAB-142Trial
SAB initiates Phase 2b SAFEGUARD study for SAB-142
new-onset Stage 3 autoimmune type 1 diabetessource ↗
▲Primary Endpoint MetClinical Data
MELD-ATG study met primary endpoint of C-peptide preservation at 12 months
new-onset Stage 3 autoimmune type 1 diabetessource ↗
◆Oral PresentationSAB-142Presentation
Mechanism of Action of a Fully Human Anti-Thymocyte Globulin, SAB-142, for the Treatment of Type 1 Diabetes
type 1 diabetessource ↗
◆Oral PresentationPresentation
Specimen Quality for Multicenter Clinical Trials: Comparing Novel Blood Preservation Methods to Cryopreserved PBMCs
type 1 diabetessource ↗
◆Oral PresentationSAB-142Presentation
Immunomodulation Without Sustained Lymphodepletion: SAB-142, a Fully Human Anti-Thymocyte Globulin
type 1 diabetessource ↗
◆Oral PresentationSAB-142Presentation
INNODIA EASD Symposium: Life-Changing T1D Therapies Symposium
type 1 diabetessource ↗
▲Oral PresentationPresentation
Invited presentation at INNODIA-hosted symposium at EASD on MELD-ATG study results
type 1 diabetessource ↗
●Oral PresentationSAB-142Presentation
Phase 1 data presented at EASD and ISPAD
type 1 diabetessource ↗
▲Equity OfferingCorporate
Raised $175 million in oversubscribed private placement including Sanofi
▲Type B MeetingSAB-142FDA Meeting
Achieved alignment with FDA on Phase 2b SAFEGUARD study design
type 1 diabetessource ↗
▼Equity OfferingCorporate
Oversubscribed $175 million private placement with participation from Sanofi and other investors
▲Topline ReadoutSAB-142Clinical Data
Positive Phase 1 topline data for SAB-142
type 1 diabetessource ↗
▲Trial InitiationSAB-142Trial
Phase 2b SAFEGUARD initiation
newly diagnosed Stage 3 autoimmune type 1 diabetessource ↗
Past FDA Catalysts and PDUFA Decisions
How SABS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-10 | SAB-142 (human anti-thymocyte immunoglobulin) | Phase 2b data readout | Phase 2b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C57 / 100
Pipeline Score
$1.1B
Pipeline Value
Undervalued
Valuation Signal
3
Drugs Scored
3.7x
rNPV / MCap
Top 10%
Micro Cap(rank 67 of 658)
Percentile Rank
SAB Biotherapeutics, Inc. carries a moderate pipeline score (57/100), with $4.2B risk-adjusted pipeline value, led by SAB-142 in Type 1 Diabetes (Phase 3), across $88B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SAB-142 Small moleculeNCT07670650 | Type 1 Diabetes | Phase 3 | NOT YET_RECRUITING | 267 | Sep 1, 2030 |
Clinical Trial Results
Readouts, endpoints and source filings for every SABS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| SAB-142 | autoimmune Type 1 Diabetes | Phase 1 | 2026-04-22 | All 4 T1D participants receiving SAB-142 showed C-peptide preservation; 3 of the 4 participants showing a super responder profile; improved glycemic control vs baseline based on continuous glucose monitoring (CGM) time in range dataRead More | SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026 All 4 T1D participants receiving SAB-142 showed C-peptide preRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kropotova AlexandraOfficer (CHIEF MEDICAL OFFICER) | Disposition | -988 42,308 held | $0.00 | 06/25/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SABS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Vivo Capital, LLC | 2.6 % (-27.8 %) | 28.47 M | 7.30 M | -36.08% ( -4.12 M) |
SABS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SABS ranks across every disease it competes in
Competitive Position is a premium feature
See how SABS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSABS News
SABSSAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
SAB Biotherapeutics will present Phase 1 data for SAB-142 at the Breakthrough T1D Clinical & Research Congress in October 2026. The presentations will highlight the immunotherapy's mechanism of action, redosing potential, and early responses in type 1 diabetes patients. SAB-142 aims to preserve insulin-producing beta cells and change the treatment paradigm for Stage 3 T1D.
Read more →SABSSAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
SAB Biotherapeutics will present data on SAB-142 at the 62nd Annual Meeting of the EASD in Milan. The presentations will focus on the immunotherapy's mechanism of action, potential for safe redosing, and early evidence of preserving C-peptide levels in patients with Stage 3 type 1 diabetes. The company aims to engage with the scientific community during this event.
Read more →SABSSAB BIO to Participate in Upcoming Investor Conferences
SAB Biotherapeutics, Inc. will participate in two investor conferences in September 2026. CEO Samuel J. Reich will present at the Citi Biopharma Back to School Conference, followed by one-on-one meetings at the Morgan Stanley Global Healthcare Conference. The company is focused on developing treatments for autoimmune diseases, including its lead candidate SAB-142, currently in a Phase 2b trial.
Read more →SABSSAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
SAB BIO has activated over 60 clinical sites for its registrational SAFEGUARD study of SAB-142, targeting Stage 3 new onset type 1 diabetes. The company reports that enrollment is on schedule for completion by Q4 2026, with topline data anticipated in the latter half of 2027. Additionally, a grant has been awarded for the PRISE-hATG study of SAB-142.
Read more →SABSSAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
SAB Biotherapeutics, a clinical-stage biopharmaceutical company, will host a conference call on August 6, 2026, to discuss its second quarter financial results. The call is aimed at providing investors with updates on the company's developments, particularly in its efforts to treat type 1 diabetes and other autoimmune diseases. This event highlights the company's commitment to transparency and investor engagement.
Read more →SABSBreakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
Breakthrough T1D has awarded a grant to SAB Biotherapeutics to support the PRISE-hATG study. This study focuses on the use of SAB-142, a fully human anti-thymocyte immunoglobulin, for patients with Stage 3 Type 1 Diabetes. The funding aims to enhance research and development in this critical area of diabetes treatment.
Read more →SABSSAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
SAB Biotherapeutics, Inc. announced it will present data on SAB-142 at the American Diabetes Association's 2026 Scientific Sessions and the FOCIS 2026 Annual Meeting. The presentations will highlight the clinical safety and efficacy of SAB-142, a promising immunotherapy for newly diagnosed Stage 3 type 1 diabetes patients. The company aims to advance its ongoing Phase 2b SAFEGUARD study.
Read more →SABSSAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
SAB Biotherapeutics reported its Q1 2026 financial results, highlighting progress in the SAFEGUARD trial for SAB-142, aimed at treating type 1 diabetes. Enrollment is on schedule, with Phase 1 data showing improved glycemic control and C-peptide preservation. The company secured $95 million in funding, extending its operational runway through 2028. However, it also reported a significant net loss compared to the previous year.
Read more →SABSSAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
SAB Biotherapeutics, Inc. will release its first quarter 2026 financial results on May 12, 2026. A conference call and webcast will be held at 8:30 AM ET to discuss these results and provide business updates. The company is focused on developing treatments for autoimmune diseases, including its lead candidate SAB-142 for type 1 diabetes.
Read more →SABSSAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
SAB Biotherapeutics presented promising data on their Phase 1 trial of SAB-142 for treating autoimmune Type 1 Diabetes at the IDS 2026 Congress. All four participants receiving SAB-142 demonstrated preserved C-peptide levels, with three exhibiting a super responder profile. The treatment also led to improved glycemic control, indicating its potential effectiveness without increasing insulin use. This data supports the idea of SAB-142 as a promising long-term immunotherapy for patients with established T1D.
Read more →SABSSAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
SAB Biotherapeutics will present new data on SAB-142 at the upcoming Immunology of Diabetes Society Congress in Brisbane. The presentations will highlight the clinical and mechanistic profile of SAB-142, an innovative immunotherapy for type 1 diabetes. The company anticipates significant engagement with the scientific community as it progresses towards topline data readout in late 2027.
Read more →SABSSAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
SAB Biotherapeutics has successfully closed an $85 million public offering, selling over 19 million shares of common stock and pre-funded warrants. The proceeds will primarily fund the continued development of its lead candidate, SAB-142, aimed at treating type 1 diabetes. The offering was managed by notable investment banks, enhancing its credibility.
Read more →SABS▼ -9.1%on this newsshared move
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
SAB Biotherapeutics, Inc. has announced the pricing of an $85 million public offering of common stock and pre-funded warrants. The offering includes 19,324,677 shares at $3.85 each, with additional options for underwriters. Proceeds will primarily fund the development of SAB-142 for type 1 diabetes and other operational needs. The offering is expected to close on March 19, 2026, pending customary conditions.
Read more →SABSSAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SAB Biotherapeutics, Inc. has announced a proposed public offering of its common stock and pre-funded warrants as part of its efforts to fund the continued development of SAB-142, a treatment for type 1 diabetes and other autoimmune diseases. The company plans to use the funds for clinical trials, manufacturing, regulatory, and operational activities. The offering includes a 30-day option for underwriters to purchase additional shares. Market and other conditions may affect the completion and size of the offering.
Read more →SABS▲ +6.8%on this news· ran to +19% by day 1
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
SAB Biotherapeutics announced promising Phase 1 data for SAB-142, a treatment aimed at Type 1 Diabetes (T1D). The trial, which included adult patients with established T1D, showed early signs of C-peptide preservation in treated participants, suggesting a potential disease-modifying effect. A key opinion leader, Michael J. Haller, commented on the encouraging nature of the data, which aligns with the expected therapeutic mechanism. The Company is advancing SAB-142 into a more extensive Phase 2b trial called SAFEGUARD, focusing on evaluating safety and efficacy in new-onset T1D patients.
Read more →SABS▼ -5.9%on this news
SAB BIO to Participate in Upcoming February 2026 Investor Conferences
SAB Biotherapeutics, Inc. (Nasdaq:SABS) announced its participation in two investor conferences in February 2026. The events include the Guggenheim Securities Emerging Outlook: Biotech Summit on February 11 and the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25. These conferences will feature fireside chats with the company's management team, highlighting their advancements in developing treatments for type 1 diabetes and other autoimmune diseases.
Read more →SABS▲ +9.7%on this news
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
SAB Biotherapeutics has appointed David Zaccardelli, Pharm.D., as Chair of the Board and Rita Jain, M.D., as an Independent Director. Both appointments are effective immediately and are expected to enhance the company's strategic direction. Zaccardelli brings extensive biotech experience, while Jain specializes in autoimmune disease drug development. Their leadership is anticipated to significantly impact SAB BIO's growth and clinical advancements.
Read more →SABSThe material in this presentation has been prepared by SAB Biotherapeutics, Inc., doing business as SAB BIO (“SAB”) and is general background information about SAB's activities current as of the date of thi
SAB Biotherapeutics, Inc. (SAB) has provided a corporate presentation highlighting its ongoing developments in transforming treatment for Type 1 Diabetes (T1D). The company is currently conducting a registrational Phase 2b SAFEGUARD study for its lead product candidate, SAB-142, which aims to modify the disease rather than merely treat symptoms. SAB is uniquely positioned due to its proprietary multi-specific antibody platform and solid financial backing, allowing it to advance its clinical programs and address the substantial market opportunity in autoimmune diseases. The presentation detailed the expected timeline for the SAFEGUARD study and emphasized the unmet need for effective therapies in T1D care.
Read more →About SAB Biotherapeutics, Inc.
Headquarters777 W 41ST ST, MIAMI BEACH, FL, 33140
BIOPHARMAWATCH ELITE PLUS
Trade the next SABS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime